PMID- 31118790
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 11
DP  - 2019
TI  - Baseline platelet counts and derived inflammatory biomarkers: prognostic 
      relevance in metastatic melanoma patients receiving Endostar plus dacarbazine and 
      cisplatin.
PG  - 3681-3690
LID - 10.2147/CMAR.S194176 [doi]
AB  - Background: The clinical efficacy and safety of Endostar combined with 
      chemotherapy in the treatment of metastatic malignant melanoma (MM) were analyzed 
      and the indicators capable of predicting the efficacy of the regimen were 
      identified to guide clinical practice. Patients and methods: The clinical data of 
      55 patients with metastatic MM without gene mutations who were treated with 
      Endostar combined with dacarbazine and cisplatin were retrospectively analyzed. 
      Efficacy was assessed using RECIST 1.1, and adverse events (AEs) were graded 
      according to NCI-CTCAE 4.0. The log-rank test was used to compare the survival 
      curves of patients in different subgroups, and stepwise multivariate Cox 
      regression analysis was used to determine significant prognostic factors. 
      Differences were considered statistically significant at P<0.05. Results: Of the 
      55 patients, seven showed a partial response, 20 showed stable disease, and 28 
      showed progressive disease. The median progression-free survival was 17.9 months. 
      AEs were controllable. Univariate analysis identified biotherapy, clinical stage, 
      clinical classification, low baseline platelet count, platelet to albumin ratio 
      (PAR), and platelet to globulin ratio (PGR) as factors affecting drug efficacy. 
      Multivariate Cox regression analysis identified clinical stage and PAR as 
      independent factors predicting the efficacy of the regimen. Conclusions: Endostar 
      combined with chemotherapy showed a curative effect on metastatic MM without gene 
      mutations, and AEs were controllable. The baseline platelet count and derived PAR 
      and PGR values were associated with the efficacy of the regimen. The potential 
      value of efficacy prediction remains to be further verified by prospective random 
      experiments.
FAU - Yang, Lingge
AU  - Yang L
AD  - Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, People's Republic of China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      People's Republic of China.
FAU - Xu, Yu
AU  - Xu Y
AD  - Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, People's Republic of China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      People's Republic of China.
FAU - Luo, Peng
AU  - Luo P
AD  - Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, People's Republic of China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      People's Republic of China.
FAU - Chen, Shiqi
AU  - Chen S
AD  - Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, People's Republic of China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      People's Republic of China.
FAU - Zhu, Huiyan
AU  - Zhu H
AD  - Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, People's Republic of China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      People's Republic of China.
FAU - Wang, Chunmeng
AU  - Wang C
AD  - Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, People's Republic of China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20190429
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC6500443
OTO - NOTNLM
OT  - Endostar
OT  - inflammatory biomarkers
OT  - melanoma
OT  - platelet to albumin ratio
OT  - platelet to globulin ratio
OT  - targeted therapy
COIS- All authors declare that they have no competing interests in this work.
EDAT- 2019/05/24 06:00
MHDA- 2019/05/24 06:01
PMCR- 2019/04/29
CRDT- 2019/05/24 06:00
PHST- 2018/11/11 00:00 [received]
PHST- 2019/04/01 00:00 [accepted]
PHST- 2019/05/24 06:00 [entrez]
PHST- 2019/05/24 06:00 [pubmed]
PHST- 2019/05/24 06:01 [medline]
PHST- 2019/04/29 00:00 [pmc-release]
AID - 194176 [pii]
AID - 10.2147/CMAR.S194176 [doi]
PST - epublish
SO  - Cancer Manag Res. 2019 Apr 29;11:3681-3690. doi: 10.2147/CMAR.S194176. 
      eCollection 2019.